Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (observer‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (self‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel leads to lower hypoglycaemia (investigator‐defined) compared with placebo (high certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review
Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of intravenous treatment for hypoglycaemia (yes/no) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events# (e.g. choking or vomiting at time of administration) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in adverse events# (e.g. choking or vomiting at time of administration) compared with placebo (moderate certainty).
1 finding from 1 review
Separation from mother for treatment of hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in separation from mother for treatment of hypoglycaemia (infant nursed… compared with placebo (low certainty).
1 finding from 1 review
Breastfeeding (exclusive after discharge) ‐ not reported (WHO 2008 definition (yes/no)) · newborn infants at risk of neonatal hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of atrial tachyarrhythmias · Human trial participants undergoing ablation for atrial fibrillation
Class I antiarrhythmics showed no clear difference in recurrence of atrial tachyarrhythmias compared with control (low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found